2,367 Shares in Zoetis Inc. (NYSE:ZTS) Purchased by Walleye Capital LLC

Walleye Capital LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTSGet Rating) during the first quarter, HoldingsChannel reports. The institutional investor bought 2,367 shares of the company’s stock, valued at approximately $446,000.

Other hedge funds have also recently bought and sold shares of the company. Martin Currie Ltd. increased its stake in Zoetis by 2.5% in the 1st quarter. Martin Currie Ltd. now owns 107,471 shares of the company’s stock worth $20,268,000 after purchasing an additional 2,571 shares in the last quarter. Ninety One UK Ltd grew its stake in Zoetis by 11.5% during the 1st quarter. Ninety One UK Ltd now owns 94,422 shares of the company’s stock valued at $17,807,000 after acquiring an additional 9,742 shares in the last quarter. Midwest Wealth Management Inc. grew its stake in Zoetis by 4.7% during the 1st quarter. Midwest Wealth Management Inc. now owns 9,213 shares of the company’s stock valued at $1,737,000 after acquiring an additional 410 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Zoetis by 66.8% during the 1st quarter. EverSource Wealth Advisors LLC now owns 342 shares of the company’s stock valued at $65,000 after buying an additional 137 shares during the last quarter. Finally, M Holdings Securities Inc. acquired a new stake in shares of Zoetis during the 1st quarter valued at about $587,000. 91.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ZTS shares. The Goldman Sachs Group reduced their price target on Zoetis from $208.00 to $202.00 and set a “buy” rating for the company in a report on Thursday, July 21st. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Friday, August 5th. Stifel Nicolaus reduced their price target on Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a report on Friday, June 24th. Finally, Piper Sandler began coverage on Zoetis in a report on Monday, July 11th. They set an “overweight” rating and a $205.00 price target for the company. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $224.00.

Zoetis Stock Down 1.2 %

Shares of ZTS opened at $149.46 on Friday. The company has a current ratio of 2.18, a quick ratio of 1.46 and a debt-to-equity ratio of 1.14. Zoetis Inc. has a 12 month low of $148.96 and a 12 month high of $249.27. The firm’s 50 day moving average is $167.61 and its 200-day moving average is $173.54. The stock has a market capitalization of $69.97 billion, a PE ratio of 33.89, a P/E/G ratio of 2.67 and a beta of 0.77.

Zoetis (NYSE:ZTSGet Rating) last released its earnings results on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.22 by ($0.02). Zoetis had a net margin of 26.14% and a return on equity of 49.03%. The firm had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.03 billion. During the same period in the prior year, the business earned $1.19 earnings per share. Zoetis’s quarterly revenue was up 7.8% compared to the same quarter last year. Equities research analysts forecast that Zoetis Inc. will post 5.01 EPS for the current year.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 2,167 shares of the company’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $180.26, for a total value of $390,623.42. Following the completion of the transaction, the executive vice president now owns 23,687 shares of the company’s stock, valued at approximately $4,269,818.62. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Zoetis news, EVP Roxanne Lagano sold 2,167 shares of the business’s stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $180.26, for a total transaction of $390,623.42. Following the sale, the executive vice president now directly owns 23,687 shares of the company’s stock, valued at approximately $4,269,818.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kristin C. Peck sold 9,689 shares of the company’s stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $180.00, for a total transaction of $1,744,020.00. Following the completion of the transaction, the chief executive officer now owns 39,743 shares of the company’s stock, valued at $7,153,740. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,501 shares of company stock valued at $2,949,073. 0.12% of the stock is currently owned by insiders.

Zoetis Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.